Plasmid DNA was key to the development of biologic drug manufacturing. Today, it plays a critical role in the production of next-generation cell and gene therapies and vaccines. With its plasmid DNA manufacturing expertise, Aldevron has helped facilitate the advance of these important therapeutics. The company continues to invest in additional capacity and novel capabilities to support biopharma manufacturers into the future.
Aldevron, a global leader in the manufacture of plasmid DNA, mRNA and proteins, has promoted Venkata Indurthi to Vice President of Research and Development (R&D). He will begin this new role immediately and continue reporting to John Ballantyne, Co-founder and Chief Scientific Officer while having direct access to Aldevron’s senior executive team.
Aldevron has added GMP gene synthesis to its array of services. This expanded capability will be used primarily to support Aldevron’s clients who require rapid GMP gene synthesis for novel cancer treatments based on neoantigens. The company noted the service is not suited for routine, research-grade synthesis, for which Aldevron will continue using outside providers.
